AUTHOR=Guo Fang , Yi Li , Zhang Wei , Bian Zhi-Jie , Zhang Yong-Bo 

TITLE=Association Between Z Drugs Use and Risk of Cognitive Impairment in Middle-Aged and Older Patients With Chronic Insomnia

JOURNAL=Frontiers in Human Neuroscience

VOLUME=15

YEAR=2021

URL=https://www.frontiersin.org/journals/human-neuroscience/articles/10.3389/fnhum.2021.775144

DOI=10.3389/fnhum.2021.775144

ISSN=1662-5161

ABSTRACT=<p><bold>Background:</bold> Benzodiazepines (BZDs) and Non-BZDs (NBZDs) have been widely used for patients with chronic insomnia. Long-term uses of BZDs may cause cognitive impairment and increase the risk for dementia in older patients. NBZD as an agonist of the GABA<sub>A</sub> receptor complex includes eszopiclone, zopiclone, zolpidem, and zaleplon, also collectively known as Z drugs. However, evaluations for an association between cognitive impairment and Z drug use have been limitedly performed. This study aimed to investigate the association between the risk of cognitive decline and exposure to Z drugs in middle-aged and older patients with chronic insomnia.</p><p><bold>Methods:</bold> Investigations were performed on patients with chronic insomnia who visited the outpatient Department of Neurology, Beijing Friendship Hospital, and were assessed for the global cognitive function (MoCA) and memory (AVLT), executive function (TMT-B), visuospatial ability (CDT), verbal function (BNT-30), and attention (DST). Multiple regression analysis was conducted to determine the independent factors of cognition and evaluated the effect of Z drug use (zolpidem and zopiclone) on cognition.</p><p><bold>Results:</bold> A total of 120 subjects were identified. In our analysis, BZD exposure density (<italic>P</italic> = 0.025, OR = 1.43, 95% CI, 1.25–1.86) was an independent risk factor of cognitive impairment in middle-aged and older patients with chronic insomnia. Neither Z drug use (<italic>P</italic> = 0.103) nor Z drug exposure density (<italic>P</italic> = 0.765) correlated with global cognitive function. Moreover, there was a positive association between Z drug use and attention [(<italic>P</italic> = 0.002, OR = 0.42, 95% CI, 0.24–0.73)]. Additionally, income level (<italic>P</italic> = 0.001, OR = 0.23, 95% CI, 0.10–0.53), severity of insomnia (<italic>P</italic> = 0.019, OR = 1.20, 95% CI, 1.03–1.40) and age (<italic>P</italic> = 0.044, OR = 1.07, 95% CI, 1.00–1.14) were also independent factors of global cognitive function.</p><p><bold>Conclusion:</bold> BZD exposure density was an independent risk factor of cognitive impairment in middle-aged and older patients with chronic insomnia, but no correlation was found between Z drug use and cognitive impairment. Moreover, the use of Z drugs seemed to be associated with protection for attention. The use for prescription of BZDs, in this case, should be avoided or limited to low doses. Due to the addiction and tolerance, Z drugs should also be prescribed with great caution in middle-aged and elderly patients.</p>